Appendix A – Technology Specific Terms and Conditions Appendix B – Diligence Report Appendix C – Form of Royalty ReportExclusive License Agreement • June 28th, 2013 • Omni Bio Pharmaceutical, Inc. • Biological products, (no disgnostic substances) • Colorado
Contract Type FiledJune 28th, 2013 Company Industry JurisdictionThis Exclusive License Agreement (the “Agreement”) between the Regents of the University of Colorado, a body corporate, having its principal office at 1800 Grant Street, 8th Floor, Denver, CO 80203 (hereinafter “University”) and Omni Bio Pharmaceutical, Inc., a Colorado corporation, having its principal office at 5350 S. Roslyn Street, Suite 430, Greenwood Village, CO 80111 (hereinafter “Licensee”) is effective on the 18th of February, 2013, (the “Effective Date”).
Appendix A – Technology Specific Terms and Conditions Appendix B – Diligence Report Appendix C – Form of Royalty ReportExclusive License Agreement • June 28th, 2013 • Omni Bio Pharmaceutical, Inc. • Biological products, (no disgnostic substances) • Colorado
Contract Type FiledJune 28th, 2013 Company Industry JurisdictionThis Exclusive License Agreement (the “Agreement”) between the Regents of the University of Colorado, a body corporate, having its principal office at 1800 Grant Street, 8th Floor, Denver, CO 80203 (hereinafter “University”) and Omni Bio Pharmaceutical, Inc., a Colorado corporation, having its principal office at 5350 S. Roslyn Street, Suite 430, Greenwood Village, CO 80111 (hereinafter “Licensee”) is effective on the 18th of January, 2013, (the “Effective Date”).
Appendix A – Technology Specific Terms and Conditions Appendix B – Diligence Report Appendix C – Form of Royalty ReportExclusive License Agreement • October 2nd, 2012 • Omni Bio Pharmaceutical, Inc. • Biological products, (no disgnostic substances) • Colorado
Contract Type FiledOctober 2nd, 2012 Company Industry JurisdictionThis Exclusive License Agreement (the “Agreement”) between the Regents of the University of Colorado, a body corporate, having its principal office at 1800 Grant Street, 8th Floor, Denver, CO 80203 (hereinafter “University”) and Omni Bio Pharmaceutical, Inc., a Colorado corporation, having its principal office at 5350 S. Roslyn Street, Suite 430, Greenwood Village, CO 80111 (hereinafter “Licensee”) is effective on the 26th of September, 2012, (the “Effective Date”).